There are currently 82 active clinical trials seeking participants for Cervical Cancer research studies. The states with the highest number of trials for Cervical Cancer participants are California, Texas, New York and Ohio.
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Northwestern University Robert H Lurie Medical Research, Chicago, Illinois +3 locations
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: HonorHealth Research and Innovation Institute, Scottsdale, Arizona +20 locations
Conditions: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Register for Updates
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228
Recruiting
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/18/2025
Locations: Providence Medical Foundation (site 209), Santa Rosa, California +14 locations
Conditions: Mesothelioma, Ovarian Cancer, Adenoid Cystic Carcinoma, Cervical Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymic Carcinoma, Bladder Cancer, Pancreatic Cancer, Head and Neck Carcinoma, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Sarcoma, Esophageal Cancer, Uterine Cancer, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
Register for Updates
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194
Recruiting
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Sarah Cannon Research Institute, Denver, Colorado +5 locations
Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer
Register for Updates
ASk Questions in GYnecologic Oncology (ASQ-GYO)
NCT06339827
Recruiting
The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge compared to usual care during new patient gynecologic oncology visits. Also to determine the acceptability of the ASQ-GYO QPL with new gynecologic oncology patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Gestational Trophoblastic Disease
Register for Updates
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: City of Hope, Duarte, California +62 locations
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
Register for Updates
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT05051722
Recruiting
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal flui... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Mayo Clinic, Phoenix, Arizona +19 locations
Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Register for Updates
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
NCT05475171
Recruiting
To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer, Cervical Cancer
Register for Updates
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: City of Hope, Duarte, California +9 locations
Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Register for Updates
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT04038619
Recruiting
This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Register for Updates
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
NCT05952141
Recruiting
Investigators will test the effectiveness of adaptive strategies on timely adoption of cervical cancer treatment in Botswana using a pragmatic trial design.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +2 locations
Conditions: Cervical Cancer
Register for Updates
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
NCT05359016
Recruiting
The goal of this operational research study is to develop, implement and test integrated CCS\&PT and voluntary FP service delivery models to evaluate whether integrated service delivery can optimize uptake and health impact of both services. The study objectives and learning questions are listed below, along with key outcomes that will be measured.
Gender:
FEMALE
Ages:
Between 30 years and 49 years
Trial Updated:
05/09/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Cervical Cancer
Register for Updates